pyrazines has been researched along with Angiogenesis, Pathologic in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 42 (59.15) | 29.6817 |
| 2010's | 29 (40.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, F; Cui, H; Feng, W; Guo, W; Lei, H; Li, G; Li, T; Wang, P; Wang, S; Xu, B; Yang, Y; Yuan, Y; Zhang, B; Zhang, N | 1 |
| Iqbal, MK; Li, J; Li, K; Luo, H; Mehmood, K; Nabi, F; Rehman, MU; Shahzad, M; Wang, L; Zhang, H | 1 |
| Iqbal, M; Iqbal, MK; Jiang, X; Li, J; Mehmood, K; Qamar, H; Rehman, MU; Tong, X; Waqas, M; Yao, W; Zhang, H; Zhang, J | 1 |
| Ge, J; Lai, Z; Qiu, J; Tang, M; Wu, C; Wu, Y; Xu, Z; Yang, M; Yang, Y; Yu, K; Zhuang, J | 1 |
| Belloni, D; Berenzi, A; Caligaris-Cappio, F; Ferrarini, M; Ferrero, E; Girlanda, S; Mazzoleni, G; Ponzoni, M; Steimberg, N | 1 |
| Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J | 1 |
| Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
| Cai, X; Chen, P; Chen, Z; Ge, J; Hu, H; Li, K; Pan, X; Xia, L; Yang, Y; Yu, K; Zhang, J; Zhuang, J | 1 |
| Chambers, JE; Clarke, HJ; Liniker, E; Marciniak, SJ | 1 |
| Chung, S; Jeon, J; Kamm, RD; Kasuya, J; Kim, C | 1 |
| Amin, HM; Angelo, LS; Falchook, GS; Hess, K; Hong, D; Howard, AN; Huang, M; Jackson, EF; Janku, F; Kurzrock, R; Lawhorn, KN; Naing, A; Ng, CS; Parkhurst, KL; Tannir, NM; Vishwamitra, D; Wheler, JJ | 1 |
| Chen, W; Jiang, Y; Lin, N; Liu, C; Wang, C; Wang, H | 1 |
| Apuy, J; Bissonette, R; Canan, SS; Cathers, BE; Fultz, KE; Gamez, JC; Ghoreishi, K; Hickman, M; Khambatta, G; Leisten, J; Moghaddam, MF; Mortensen, DS; Narla, RK; Packard, G; Peng, SX; Perrin-Ninkovic, S; Raymon, HK; Richardson, S; Sankar, S; Shi, T; Tong, Z; Tran, T; Worland, P; Xu, S; Xu, W; Yang, WQ; Zhao, J | 1 |
| Dai, Y; Doeppner, TR; Hermann, DM; Jin, F; Kuckelkorn, U; Li, F; Li, W; Li, X; Li, Z; Liu, L; Qiu, L; Zang, M; Zhou, W | 1 |
| Lin, Q; Qian, L; Shao, J; Zhang, C; Zhang, F; Zhang, Z; Zhao, S; Zheng, S | 1 |
| Chen, A; Hao, M; Jin, H; Lian, N; Shao, J; Wu, L; Yao, Z; Zhang, F; Zheng, S | 1 |
| Chen, A; Shao, J; Yao, Z; Zhang, F; Zhang, Z; Zhao, S; Zheng, S | 1 |
| McConkey, DJ | 1 |
| Brandes, G; Buer, J; Carlomagno, T; Frank, R; Geffers, R; Gossler, A; Gütgemann, I; Kalesse, M; Kubicka, S; Malek, NP; Manns, MP; Menche, D; Nickeleit, I; Sasse, F; Sörensen, I; Steinmetz, H; Zender, S | 1 |
| Diehl, JA; Herlyn, M; Klein-Szanto, A; Lioni, M; Noma, K; Rustgi, AK; Smalley, KS; Snyder, A | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Chen, L; Gao, M; Lei, N; Lu, Y; Wang, AY; Wu, JM; Xu, B; Zhang, CB; Zhang, LJ; Zhang, WW; Zheng, SZ | 1 |
| Arts, J; Coulton, L; Croucher, P; De Raeve, H; Deleu, S; Lemaire, M; Menu, E; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K | 1 |
| Brooks, SC; Choi, JH; Kim, SG; Kim, YW; Lee, MO; Lee, WH | 1 |
| D'Auria, F; Dammacco, F; Di Pietro, G; Ditonno, P; Gnoni, A; Guarini, A; Mangialardi, G; Moschetta, M; Musto, P; Ria, R; Ribatti, D; Ricciardi, MR; Vacca, A | 1 |
| Babcock, T; Bannerman, B; Cao, Y; Hatsis, P; Kupperman, E; Robertson, R; Silva, MD; Terkelsen, J; Williamson, MJ; Xia, C; Yu, L | 1 |
| Dana, K; Hana, S; Jaroslav, M; Jiri, V; Lucie, K; Ludek, P; Marta, K; Martina, A; Miroslav, P; Roman, H; Tomas, B; Zdenek, A | 1 |
| Adamo, V; Bronte, G; Cicero, G; Fulfaro, F; Gebbia, N; Rizzo, S; Russo, A | 1 |
| Blackwell, TS; Kalomenidis, I; Karabela, SP; Kollintza, A; Magkouta, S; Moschos, C; Psallidas, I; Roussos, C; Sherrill, TP; Stathopoulos, GT; Theodoropoulou, P | 1 |
| Chiriva-Internati, M; Chui, K; Cobos, E; Jenkins, MR; John, CM; Mirandola, L; Yu, Y | 1 |
| Kang, SG; Kim, SG; Lee, WH; Lee, YH; Lee, YS | 1 |
| Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W | 1 |
| Berenson, JR; Chen, H; Li, J; Li, M; Nichols, CM; Sanchez, E; Wang, C | 1 |
| Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
| Wang, X; Yao, C; Zhang, Z | 1 |
| Araujo, ME; Bates, SE; Bishton, M; Dai, Y; Grant, S; Harrison, SJ; Johnstone, RW; Lee, B; Piekarz, RL; Prince, HM | 1 |
| Fujisawa, K; Hara, K; Kinouchi, M; Kuribayashi, N; Miyamoto, Y; Nagai, H; Ohe, G; Takamaru, N; Tamatani, T; Uchida, D | 1 |
| Adams, J; Anderson, KC; Catley, LP; Goloubeva, O; Gupta, D; Hideshima, T; LeBlanc, R; Lentzsch, S; Mitsiades, CS; Mitsiades, N; Munshi, NC; Neuberg, D; Pien, CS; Richardson, PG | 1 |
| Logothetis, C; McConkey, DJ; Papandreou, C; Pettaway, C; Song, R; Williams, S | 1 |
| McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG | 1 |
| Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y | 1 |
| Hattori, K; Nakajima, M; Nakashima, E; Oku, N; Tamura, M; Tsukada, H; Unno, K; Yonezawa, S | 1 |
| Capriotti, T | 1 |
| Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA | 1 |
| Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
| Matono, K; Mizobe, T; Nagase, H; Nakajima, M; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
| Apperley, JF; Crawley, D; Lampert, I; Naresh, K; Politou, M; Rahemtulla, A; Terpos, E | 1 |
| Harada, K; Sato, M; Yoshida, H | 1 |
| Daniel, KG; Dou, QP; Kazi, A; Kuhn, DJ | 1 |
| Bay, JO; Blay, JY; Rixe, O; Spano, JP | 1 |
| Behrens, D; Cinatl, J; Doerr, HW; Fichtner, I; Haider, W; Mack, A; Michaelis, M; Rothweiler, F | 1 |
| Anderson, KC; Dammacco, F; Hideshima, T; Ishitsuka, K; Kumar, S; Nico, B; Raje, N; Ribatti, D; Richardson, PG; Roccaro, AM; Shiraishi, N; Vacca, A; Yasui, H | 1 |
| Albanell, J; Montagut, C; Rovira, A | 1 |
| Goranov, SE; Goranova-Marinova, VS | 1 |
| Burtrum, D; Ludwig, DL; Moore, MA; Wu, KD; Zhou, L | 1 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Brignole, C; Cilli, M; Cioni, M; Corrias, MV; Di Paolo, D; Marimpietri, D; Nico, B; Pagnan, G; Pastorino, F; Pezzolo, A; Piccardi, F; Pistoia, V; Ponzoni, M; Ribatti, D | 1 |
| Hideshima, T; Yasui, H | 1 |
| Benedict, WF; Dinney, C; Kamat, A; McConkey, DJ; Papageorgiou, A | 1 |
| Davidoff, AM; Dickson, PV; Hamner, JB; Ng, CY; Sims, TL; Spence, Y; Zhou, J | 1 |
| Abayomi, EA; Jacobs, P; Sissolak, G | 1 |
| Anderson, KC; Brahmandam, M; Chauhan, D; Hideshima, T; Munshi, N; Palladino, MA; Podar, K; Richardson, P; Singh, A | 1 |
| Bladé, J; Cibeira, MT; Cid, MC; Filella, X; Lozano, E; Rosiñol, L; Rozman, M; Segarra, M | 1 |
| Canestaro, M; Ciancia, E; Fazzi, R; Galimberti, S; Marasca, R; Petrini, M | 1 |
| Anargyrou, K; Angelopoulou, MK; Christoulas, D; Dimitriadou, EM; Dimopoulos, MA; Kalpadakis, C; Kyrtsonis, MC; Masouridis, S; Panayiotidis, P; Pangalis, GA; Pouli, A; Sachanas, S; Terpos, E; Tsionos, K; Tzenou, T; Vassilakopoulos, TP | 1 |
| Accornero, P; Bersani, F; Crepaldi, T; Miretti, S; Morotti, A; Ponzetto, C; Taulli, R | 1 |
| Li, X; Pennisi, A; Yaccoby, S | 1 |
| Adams, J; Chen, Z; Crowl Bancroft, C; Dong, G; Elliott, P; Sausville, E; Sunwoo, JB; Van Waes, C; Yeh, N | 1 |
| Angeles, T; Clapper, ML; Robinson, C; Ruggeri, BA; Wilkinson, J | 1 |
| Hussein, MA | 1 |
12 review(s) available for pyrazines and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Endoplasmic reticulum stress in malignancy.
Topics: Activating Transcription Factor 6; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Neoplasms; Neovascularization, Pathologic; Protein Folding; Protein Serine-Threonine Kinases; Pyrazines; Unfolded Protein Response | 2014 |
Targeting proteasome inhibition in hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Hematologic Neoplasms; Humans; Multienzyme Complexes; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
New oncology strategy: molecular targeting of cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome inhibition: a new approach for the treatment of malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Primates; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rodentia | 2005 |
The proteasome: a novel target for anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Drug Design; Humans; Multiple Myeloma; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Randomized Controlled Trials as Topic; Ubiquitin | 2006 |
Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Molecular Structure; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines | 2005 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
[Proteasome inhibitor bortezomib as an anticancer drug].
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Clinical Trials as Topic; Cytokines; Heat-Shock Proteins; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts.
Topics: Active Transport, Cell Nucleus; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Cycle; Cell Differentiation; Clinical Trials, Phase II as Topic; Endoplasmic Reticulum; Humans; Lymphoma; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome | 2002 |
2 trial(s) available for pyrazines and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma, Renal Cell; Fatigue; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Recurrence; Thrombospondins | 2010 |
57 other study(ies) available for pyrazines and Angiogenesis, Pathologic
| Article | Year |
|---|---|
BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation.
Topics: Animals; Betulinic Acid; Caenorhabditis elegans; Chorioallantoic Membrane; Drug Discovery; Human Umbilical Vein Endothelial Cells; Humans; Metabolomics; Neovascularization, Pathologic; Pentacyclic Triterpenes; Pyrazines; Triterpenes | 2019 |
Effect of tetramethylpyrazine on tibial dyschondroplasia incidence, tibial angiogenesis, performance and characteristics via HIF-1α/VEGF signaling pathway in chickens.
Topics: Animals; Chickens; Hypoxia-Inducible Factor 1, alpha Subunit; Incidence; Neovascularization, Pathologic; Osteochondrodysplasias; Poultry Diseases; Pyrazines; Signal Transduction; Thiram; Tibia; Vascular Endothelial Growth Factor A | 2018 |
Ligustrazine recovers thiram-induced tibial dyschondroplasia in chickens: Involvement of new molecules modulating integrin beta 3.
Topics: Animals; Chickens; Gene Expression Regulation; Growth Plate; Integrin beta3; Neovascularization, Pathologic; Osteochondrodysplasias; Pesticides; Poultry Diseases; Pyrazines; Thiram; Tibia | 2019 |
Tetramethylpyrazine (TMP) ameliorates corneal neovascularization via regulating cell infiltration into cornea after alkali burn.
Topics: Alkalies; Animals; Burns, Chemical; Cell Line; Cell Movement; Cornea; Corneal Neovascularization; Disease Models, Animal; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrazines; Receptors, CXCR4; Signal Transduction; Up-Regulation | 2019 |
Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.
Topics: Adult; Aged; Angiopoietin-2; Animals; beta 2-Microglobulin; Bioreactors; Bone and Bones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Culture Techniques; Female; Genetic Markers; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Tibia; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF-1/CXCR4 axis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Cell Movement; Chemokine CXCL12; Cornea; Humans; Lung; Male; Neovascularization, Pathologic; Platelet Aggregation; Platelet Aggregation Inhibitors; Pulmonary Fibrosis; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Signal Transduction; Thrombosis | 2014 |
A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Microfluidic Analytical Techniques; Neovascularization, Pathologic; Pyrazines; Vascular Endothelial Growth Factor A | 2015 |
Tetramethylpyrazine enhances vascularization and prevents osteonecrosis in steroid-treated rats.
Topics: Adipocytes; Adipose Tissue; Animals; Bone Density; Down-Regulation; Femur Head; Male; Neovascularization, Pathologic; Osteonecrosis; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Steroids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; HCT116 Cells; HEK293 Cells; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, SCID; Molecular Structure; Multiprotein Complexes; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrazines; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Butanes; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Tetramethylpyrazine attenuates carbon tetrachloride-caused liver injury and fibrogenesis and reduces hepatic angiogenesis in rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Becaplermin; Carbon Tetrachloride; Down-Regulation; Endothelial Cells; Hepatocytes; Liver; Liver Cirrhosis; Male; Neovascularization, Pathologic; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-sis; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Canonical hedgehog signalling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis.
Topics: Animals; Benzoquinones; Carbon Tetrachloride; Disease Models, Animal; Hedgehog Proteins; Hepatic Stellate Cells; HSP90 Heat-Shock Proteins; Hypoxia-Inducible Factor 1, alpha Subunit; Lactams, Macrocyclic; Liver Cirrhosis; Male; Mice; Mice, Inbred ICR; Mustard Compounds; Neovascularization, Pathologic; Phenylpropionates; Pyrazines; Rats; Rats, Sprague-Dawley; Signal Transduction; Smoothened Receptor | 2017 |
Tetramethylpyrazine attenuates sinusoidal angiogenesis via inhibition of hedgehog signaling in liver fibrosis.
Topics: Animals; Carbon Tetrachloride; Cell Proliferation; Gene Expression Regulation; Hedgehog Proteins; Humans; Liver Cirrhosis; Mice; Neovascularization, Pathologic; Nitric Oxide; Nitric Oxide Synthase; Primary Cell Culture; Pyrazines; Smoothened Receptor | 2017 |
A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Humans; Intracellular Signaling Peptides and Proteins; Necrosis; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Time Factors; Up-Regulation | 2008 |
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Necrosis; Neoplasms; Neovascularization, Pathologic; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Esophageal Neoplasms; G2 Phase; Histones; Mice; Mice, Inbred NOD; Mitosis; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pyrazines; Remission Induction; Xenograft Model Antitumor Assays | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Female; Fibroblasts; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Pyrazines; Rats; Vascular Endothelial Growth Factor A | 2009 |
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Disease Models, Animal; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Myeloma; Neovascularization, Pathologic; Osteolysis; Pyrazines | 2009 |
Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect.
Topics: Adenylate Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Free Radical Scavengers; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; Mice; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Protein Stability; Pyrazines; Ribosomal Protein S6 Kinases, 70-kDa; Thiones; Thiophenes; Transcription, Genetic; Ubiquitin | 2009 |
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Macrophages; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Pyrazines; Vascular Endothelial Growth Factor Receptor-2; Zoledronic Acid | 2010 |
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Magnetic Resonance Imaging; Male; Metabolic Clearance Rate; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2009 |
Bortezomib: a new pro-apoptotic agent in cancer treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Humans; Mice; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2010 |
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Inflammation; Inflammation Mediators; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Pleural Effusion, Malignant; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2010 |
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Dependovirus; Drug Synergism; Endothelial Cells; Fibroblast Growth Factor 2; Galectin 3; Green Fluorescent Proteins; Humans; Immunoglobulin E; Immunoglobulin lambda-Chains; Integrin alphaVbeta3; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Umbilical Veins; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; HT29 Cells; Humans; Hydrogen Peroxide; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; MicroRNAs; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Pyridazines; Pyrroles; Thiones; Thiophenes | 2012 |
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Anti-myeloma effects of the novel anthracycline derivative INNO-206.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Hydrazones; Mice; Multiple Myeloma; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrazines | 2012 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Movement; Cell Proliferation; Cells, Cultured; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Vascular Endothelial Growth Factor A | 2012 |
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Depsipeptides; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphoma, T-Cell, Cutaneous; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines | 2012 |
Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Proteins; Interleukin-6; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; NF-kappa B; NF-KappaB Inhibitor alpha; Poly(ADP-ribose) Polymerases; Pyrazines; Radiation-Sensitizing Agents; Transcription Factor RelA; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Dose-Response Relationship, Drug; Humans; Male; Mice; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cysteine Endopeptidases; Endothelium, Vascular; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
In vivo trafficking of endothelial progenitor cells their possible involvement in the tumor neovascularization.
Topics: Animals; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluorodeoxyglucose F18; Gamma Rays; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrazines; Rats; Stem Cells; Sulfonamides; Tomography, Emission-Computed | 2004 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide | 2004 |
Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat.
Topics: Administration, Oral; Animals; Apoptosis; Chemoprevention; Colonic Neoplasms; Humans; Hydroxamic Acids; Lung Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Pyrazines; Rats; Rats, Nude; Sulfonamides; Survival Analysis; Transplantation, Heterologous | 2006 |
Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Ribonuclease, Pancreatic; Vascular Endothelial Growth Factor A | 2005 |
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protein Binding; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vincristine | 2006 |
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Growth Processes; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Neovascularization, Pathologic; Neovascularization, Physiologic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2006 |
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Receptor, IGF Type 1; Structure-Activity Relationship; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Mice; Mitotic Index; Neovascularization, Pathologic; Neuroblastoma; Protease Inhibitors; Pyrazines; Transplantation, Heterologous; Tumor Stem Cell Assay | 2006 |
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Fibroblast Growth Factor 2; Humans; Interferon-alpha; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; In Vitro Techniques; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Pyrazines; Soft Tissue Neoplasms; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2007 |
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Endoplasmic Reticulum; Heat-Shock Proteins; Humans; Lactones; Mice; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillaries; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Prognosis; Pyrazines; Thalidomide | 2008 |
Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
Topics: Boronic Acids; Bortezomib; Colony-Forming Units Assay; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Primary Myelofibrosis; Pyrazines; Tissue Culture Techniques | 2008 |
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Receptor, TIE-2; Salvage Therapy; Treatment Outcome | 2008 |
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rhabdomyosarcoma; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Role of decorin in the antimyeloma effects of osteoblasts.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Coculture Techniques; Cyclin-Dependent Kinase Inhibitor p21; Decorin; Extracellular Matrix Proteins; Genetic Vectors; Humans; Lentivirus; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Osteoblasts; Plasma Cells; Proteoglycans; Pyrazines; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2008 |
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cysteine Endopeptidases; Cytokines; Disease Models, Animal; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Multienzyme Complexes; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Cell Division; Dose-Response Relationship, Drug; Endothelium, Vascular; Hemangiosarcoma; Humans; Insulin-Like Growth Factor I; Liver; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic; Thiones; Thiophenes; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |